Expression of E-tetramer, NKG2A, and CD94 on CD3+ and CD56+ subpopulations of lymphocytes from HTLV-1-infected individuals and healthy control
Subject group . | No. . | Mean±SD . | P, ANOVA or KW . | P, Sheffé F . |
---|---|---|---|---|
E tetramer positive | ||||
HAM/TSP | 20 | 9.10±8.09 | ||
AC | 20 | 12.47±6.67 | .059 | NA |
Healthy | 22 | 14.76±7.82 | ||
NKG2A+ | ||||
HAM/TSP | 20 | 6.09±3.60 | ||
AC | 20 | 9.35±6.73 | .24* | .36 (HAM-healthy) |
Healthy | 22 | 10.87±6.53 | ||
CD94+ | ||||
HAM/TSP | 20 | 14.16±12.02 | ||
AC | 20 | 14.87±7.16 | .27 | NA |
Healthy | 22 | 18.88±9.38 | ||
CD3+ E tetramer positive | ||||
HAM/TSP | 20 | 2.81±1.87 | ||
AC | 20 | 7.39±5.85 | .001* | .013 (HAM-AC) |
Healthy | 22 | 6.78±5.37 | .03 (HAM-healthy) | |
% CD3+NKG2A+ | ||||
HAM/TSP | 20 | 2.94±2.10 | ||
AC | 20 | 6.60±5.82 | .013* | .048 (HAM-healthy) |
Healthy | 22 | 6.16±4.93 | ||
% CD3+CD94+ | ||||
HAM/TSP | 20 | 3.68±2.39 | .013 (HAM-AC) | |
AC | 20 | 8.26±5.64 | .003* | .041 (HAM-healthy) |
Healthy | 22 | 7.62±5.22 | ||
% CD56+CD3- E tetramer positive | ||||
HAM/TSP | 20 | 7.90±8.07 | ||
AC | 20 | 7.35±5.57 | .12 | NA |
Healthy | 22 | 12.47±9.11 | ||
% CD56+CD3-NKG2A+ | ||||
HAM/TSP | 20 | 5.17±4.19 | ||
AC | 20 | 5.49±5.49 | .15 | NA |
Healthy | 22 | 6.94±4.43 | ||
% CD56+CD3-CD94+ | ||||
HAM/TSP | 20 | 13.40±13.06 | ||
AC | 20 | 10.63±7.28 | .078* | NA |
Healthy | 22 | 18.87±11.05 |
Subject group . | No. . | Mean±SD . | P, ANOVA or KW . | P, Sheffé F . |
---|---|---|---|---|
E tetramer positive | ||||
HAM/TSP | 20 | 9.10±8.09 | ||
AC | 20 | 12.47±6.67 | .059 | NA |
Healthy | 22 | 14.76±7.82 | ||
NKG2A+ | ||||
HAM/TSP | 20 | 6.09±3.60 | ||
AC | 20 | 9.35±6.73 | .24* | .36 (HAM-healthy) |
Healthy | 22 | 10.87±6.53 | ||
CD94+ | ||||
HAM/TSP | 20 | 14.16±12.02 | ||
AC | 20 | 14.87±7.16 | .27 | NA |
Healthy | 22 | 18.88±9.38 | ||
CD3+ E tetramer positive | ||||
HAM/TSP | 20 | 2.81±1.87 | ||
AC | 20 | 7.39±5.85 | .001* | .013 (HAM-AC) |
Healthy | 22 | 6.78±5.37 | .03 (HAM-healthy) | |
% CD3+NKG2A+ | ||||
HAM/TSP | 20 | 2.94±2.10 | ||
AC | 20 | 6.60±5.82 | .013* | .048 (HAM-healthy) |
Healthy | 22 | 6.16±4.93 | ||
% CD3+CD94+ | ||||
HAM/TSP | 20 | 3.68±2.39 | .013 (HAM-AC) | |
AC | 20 | 8.26±5.64 | .003* | .041 (HAM-healthy) |
Healthy | 22 | 7.62±5.22 | ||
% CD56+CD3- E tetramer positive | ||||
HAM/TSP | 20 | 7.90±8.07 | ||
AC | 20 | 7.35±5.57 | .12 | NA |
Healthy | 22 | 12.47±9.11 | ||
% CD56+CD3-NKG2A+ | ||||
HAM/TSP | 20 | 5.17±4.19 | ||
AC | 20 | 5.49±5.49 | .15 | NA |
Healthy | 22 | 6.94±4.43 | ||
% CD56+CD3-CD94+ | ||||
HAM/TSP | 20 | 13.40±13.06 | ||
AC | 20 | 10.63±7.28 | .078* | NA |
Healthy | 22 | 18.87±11.05 |
% CD3+E tetramer positive means percent of CD3+ cells that are E tetramer positive
% CD56+CD3-E tetramer positive means percent of CD56+CD3- cells that are E tetramer positive
Values represent the mean ± SD. One-factor ANOVA was done when variance of each group was equal by Bartlett test. For multiple comparisons, we used Sheffé F to analyze statistical difference
AC indicates asymptomatic carrier
If variance of each group was different, Kruskal-Wallis test was used